OS Therapies Incorporated
AMEX:OSTXBiotechnology
+$0.10 today
- Market cap
- $53.83M
- Beta
- -0.95
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$0.91
Volume 0.50M
Average 0.71M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
OS Therapies Incorporated
AMEX:OSTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Spruce Biosciences, Inc. NASDAQ:SPRB | $133.33M | $46.39 | Not rated | -1.9 | -60.54% |
Outlook Therapeutics, Inc. NASDAQ:OTLK | $113.96M | $0.47 | Not rated | -2.1 | -78.67% |
NRx Pharmaceuticals, Inc. NASDAQ:NRXP | $98.28M | $2.27 | Not rated | -5.3 | +25.62% |
Adagene Inc. NASDAQ:ADAG | $94.50M | $2.51 | Not rated | -7.9 | +13.56% |
Equillium, Inc. NASDAQ:EQ | $86.87M | $1.37 | Not rated | -15.3 | +10.89% |
MiNK Therapeutics, Inc. NASDAQ:INKT | $53.73M | $10.53 | Not rated | -4.6 | -6.03% |
Werewolf Therapeutics, Inc. NASDAQ:HOWL | $47.92M | $0.99 | Not rated | -1.4 | +20.51% |
Coeptis Therapeutics, Inc. NASDAQ:COEP | $38.62M | $10.99 | Not rated | -8.3 | -10.24% |
Continue the stock analysis
Jump to another research area for this company.